Using CRISPR to Create Melanoma Stem Cells That Are Vulnerable Without CD133

A 20% reduction in symptoms was observed in participants receiving the treatment.

• Participants reported fewer symptoms after receiving the treatment compared to baseline levels.
• The reduction in symptoms was consistent across various assessments.
• No severe adverse effects were noted during the trial period.
• The findings suggest that the treatment may be beneficial for symptom management.
• Further research is needed to confirm these results in larger populations.

Simplified